Huiying Yan

Huiying Yan

Auto-generated profile, based on publicly available information

Huiying Yan

Department of Neurology, the Third Affiliated Clinical Hospital of the Changchun University of Chinese Medicine, Changchun, Jilin Province, People’s Republic of China

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2024 in ImmunoTargets and Therapy
Verified
Journal Article
Open access
PDF file
HYHuiying Yan
Huiying Yan
WWWei Wang
Wei Wang
TCTingting Cui
Tingting Cui
YSYanxin Shao
Yanxin Shao
MLMingquan Li
Mingquan Li
LFLina Feng
Lina Feng
Alzheimer’s disease (AD) is a fatal neurodegenerative disease with a subtle and progressive onset and is the most common type of dementia. However, its etiology and pathogenesis have not yet been fully elucidated. The common pathological manifestations of AD include extraneuronal β-amyloid deposition (Aβ), intraneuronal tau protein phosphorylation leading to the formation of ‘neurofibrillary tangles’ (NFTs), neuroinflammation, progressive loss of brain neurons/synapses, and glucose metabolism disorders. Current treatment approaches for AD primarily focus on the ‘Aβ cascade hypothesis and abnormal aggregation of hyperphosphorylation of tau proteins’, but have shown limited efficacy. Therefore, there is an ongoing need to identify more effective treatment targets for AD. The central nervous system (CNS) inflammatory response plays a key role in the occurrence and development of AD. Neuroinflammation is an immune response activated by glial cells in the CNS that usually occurs in response to stimuli such as nerve injury, infection and toxins or in response to autoimmunity. Neuroinflammation ranks as the third most prominent pathological feature in AD, following Aβ and NFTs. In recent years, the focus on the role of neuroinflammation and microglia in AD has increased due to the advancements in genome-wide association studies (GWAS) and sequencing technology. Furthermore, research has validated the pivotal role of microglia-mediated neuroinflammation in the progression of AD. Therefore, this article reviews the latest research progress on the role of neuroinflammation triggered by microglia in AD in recent years, aiming to provide a new theoretical basis for further exploring the role of neuroinflammation in the process of AD occurrence and development.

1 November 2023 in Drug Design, Development and Therapy
Verified
Journal Article
Open access
PDF file
HYHuiying Yan
Huiying Yan
LFLina Feng
Lina Feng
MLMingquan Li
Mingquan Li
Alzheimer’s disease is a prevalent form of dementia among elderly individuals and is characterized by irreversible neurodegeneration. Despite extensive research, the exact causes of this complex disease remain unclear. Currently available drugs for Alzheimer’s disease treatment are limited in their effectiveness, often targeting a single aspect of the disease and causing significant adverse effects. Moreover, these medications are expensive, placing a heavy burden on patients’ families and society as a whole. Natural compounds and extracts offer several advantages, including the ability to target multiple pathways and exhibit high efficiency with minimal toxicity. These attributes make them promising candidates for the prevention and treatment of Alzheimer’s disease. In this paper, we provide a summary of the common natural products used in Chinese medicine for different pathogeneses of AD. Our aim is to offer new insights and ideas for the further development of natural products in Chinese medicine and the treatment of AD.

17 June 2025 in Journal of Pharmacy and Pharmacology
Verified
Journal Article
Closed access
HYHuiying Yan
Huiying Yan
LFLimei Fang
Limei Fang
CQChang Qi
Chang Qi
MLMingquan Li
Mingquan Li
QSQile Song
Qile Song
LFLina Feng
Lina Feng
Objectives: Investigate Naochuxue formula’s mechanism in the treatment of subarachnoid hemorrhage. Methods: Analyzed Naochuxue formula’s active components via nontargeted metabolomics, and predicted the core targets using network pharmacology. Sprague‒Dawley rats were randomly divided into six groups: sham, model, Naochuxue formula low, medium and high dose groups, and edaravone. Neurological deficits were assessed using the modified Garcia score and tissue damage was assessed by measuring the brain water content. Blood‒brain barrier permeability was assessed using the Evans blue procedure and pathological changes in the lesion site were observed through HE staining and Nissl staining. TUNEL staining and Caspase-3 immunofluorescence were used to observe the apoptosis of neurons in the hippocampus. The distribution and expression of p-PI3K and p-AKT were determined using immunohistochemistry. The expression of the apoptosis-related genes Caspase-3, Bcl-2, and Bax was determined using RT‒PCR. Key findings: Compared with the model group, rats in the high-dose Naochuxue formula group exhibited significant improvements in neurological defects, brain histopathology, blood‒brain barrier permeability and brain edema on Day 3 posttreatment, downregulated Bax and Caspase-3 expression, and significantly upregulated p-PI3K, p-AKT, and Bcl-2 expression (all P < 0.05). Conclusions: High-dose formula for 3 days activated PI3K/AKT signaling pathway, inhibitd neuronal apoptosis, and exerted neuroprotective effects.

1 September 2025 in Drug Design, Development and Therapy
Verified
Journal Article
Open access
PDF file
BSBingbing Song
Bingbing Song
DYDongJie Yue
DongJie Yue
HYHuiying Yan
Huiying Yan
LFLina Feng
Lina Feng
MLMingquan Li
Mingquan Li
As highly prevalent chronic diseases globally, AD (Alzheimer’s disease) and T2DM (type 2 diabetes mellitus) not only severely affect the quality of life of patients but also impose a significant burden on their families. Numerous studies have gradually revealed that T2DM and AD are bidirectional risk factors, each capable of exacerbating the other. There is a notable correlation in their pathological mechanisms, primarily manifested in insulin resistance, OS (oxidative stress), and inflammatory responses. Currently, available drugs can only delay the progression of AD, such as Donepezil, Galantamine, and Carbamylcholine, making complete cures challenging to achieve. TCM (Traditional Chinese medicine) natural products exhibit characteristics such as multi-targeting, multi-pathway interactions, diverse biological activities, and relatively mild side effects, enabling synergistic intervention in both diseases. In recent years, TCM natural products have garnered increasing attention in research concentrated on the prevention and management of AD and T2DM. This article aims to comprehensively elucidate the collective pathogenic mechanism of AD and T2DM, and explore the progress of TCM natural products based on these mechanisms in the prevention and treatment of both diseases, thereby providing a theoretical foundation for the advancement of innovative treatment tactics.